Lab
Quest Diagnostics of Pennsylvania INC.
Quest Diagnostics of Pennsylvania INC. was paid $2.56M by Medicaid between Jan 2018 and Apr 2023, across 189 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 20% of everything it billed.
33Billing provider infoQUEST DIAGNOSTICS OF PENNSYLVANIA INC.
TWINSBURG, OH 44087
TWINSBURG, OH 44087
33aNPI1205854817assigned 07/18/2006
33bProvider typeClinical Medical Laboratory
28Total paid$2.56M
24GClaims290,160
24DCodes billed189
24AFirst – last monthJan 2018 – Apr 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Ohio
Rank by total paid#30 of 116
Median peer was paid$313K
This provider vs. median8.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 186,554 | $1.45M | |
| 2019 | 94,561 | $1.06M | |
| 2020 | 8,457 | $43K | |
| 2021 | 37 | $163.24 | |
| 2022 | 265 | $845.03 | |
| 2023 | 286 | $130.34 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 20% | 26,836 | 12,731 | $514K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 6.3% | 9,176 | 8,989 | $161K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 6.2% | 9,151 | 8,965 | $160K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.3% | 5,833 | 5,788 | $85K |
| 80053 | Comprehensive metabolic panel | 3.0% | 17,221 | 16,517 | $77K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.7% | 3,898 | 3,837 | $69K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.6% | 5,058 | 5,039 | $66K |
| 80061 | Lipid panel | 2.5% | 11,818 | 11,717 | $63K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.4% | 10,166 | 10,027 | $62K |
| 80050 | General health panel | 2.3% | 2,626 | 2,620 | $60K |
| 87799 | 2.2% | 909 | 890 | $57K | |
| 80321 | 2.1% | 3,568 | 1,850 | $55K |
177 more codes
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.1% | 3,971 | $53K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 17,717 | $51K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.7% | 2,845 | $44K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.7% | 2,991 | $43K |
| 80348 | 1.6% | 3,786 | $41K | |
| 80359 | 1.5% | 5,218 | $38K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.3% | 7,152 | $33K |
| 80355 | 1.2% | 4,291 | $30K | |
| 80354 | 1.1% | 4,124 | $29K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 661 | $28K |
| 86480 | 1.1% | 767 | $28K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 1.1% | 523 | $28K |
| 87522 | Neg quan hep c or qual rna | <1% | 976 | $24K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,220 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,213 | $22K |
| 80081 | <1% | 613 | $22K | |
| 80074 | <1% | 1,011 | $22K | |
| 86803 | <1% | 2,898 | $21K | |
| 82607 | <1% | 2,397 | $19K | |
| 87512 | <1% | 894 | $19K | |
| 84439 | <1% | 3,783 | $18K | |
| 80373 | <1% | 4,355 | $18K | |
| 88141 | <1% | 980 | $15K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,059 | $15K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 653 | $14K |
| 87088 | <1% | 3,293 | $14K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,369 | $13K |
| 80349 | <1% | 1,757 | $13K | |
| 80346 | <1% | 948 | $13K | |
| 80362 | <1% | 2,255 | $12K | |
| 80361 | <1% | 1,400 | $12K | |
| 82746 | <1% | 1,464 | $12K | |
| 83655 | <1% | 1,386 | $11K | |
| 84702 | <1% | 1,117 | $11K | |
| 84153 | <1% | 1,005 | $10K | |
| 87340 | <1% | 1,620 | $9K | |
| 87070 | <1% | 1,805 | $9K | |
| 84403 | <1% | 576 | $8K | |
| 85027 | <1% | 2,569 | $8K | |
| 80335 | <1% | 1,134 | $7K | |
| 82728 | <1% | 1,163 | $7K | |
| 86696 | <1% | 482 | $7K | |
| 86592 | <1% | 2,735 | $6K | |
| 86706 | <1% | 1,018 | $6K | |
| 86787 | <1% | 714 | $6K | |
| 86704 | <1% | 878 | $6K | |
| 81001 | <1% | 3,373 | $6K | |
| 86780 | <1% | 824 | $6K | |
| 84146 | <1% | 447 | $5K | |
| 86708 | <1% | 722 | $5K | |
| 87186 | <1% | 1,334 | $5K | |
| 88142 | <1% | 328 | $5K | |
| 87077 | <1% | 1,205 | $5K | |
| 82043 | <1% | 1,750 | $5K | |
| 86003 | <1% | 132 | $5K | |
| 80360 | <1% | 950 | $5K | |
| 86762 | <1% | 490 | $5K | |
| 83001 | <1% | 397 | $5K | |
| 80353 | <1% | 676 | $4K | |
| 82570 | <1% | 1,702 | $4K | |
| 83970 | <1% | 200 | $4K | |
| 87481 | <1% | 425 | $4K | |
| 87902 | <1% | 29 | $4K | |
| 83540 | <1% | 1,586 | $4K | |
| 83550 | <1% | 1,185 | $4K | |
| 87081 | <1% | 1,193 | $4K | |
| 84402 | <1% | 256 | $4K | |
| 86038 | <1% | 789 | $4K | |
| 86695 | <1% | 452 | $4K | |
| 80324 | <1% | 538 | $4K | |
| 82670 | <1% | 225 | $4K | |
| 87536 | <1% | 101 | $4K | |
| 84481 | <1% | 460 | $4K | |
| 80366 | <1% | 1,464 | $4K | |
| 80372 | <1% | 1,719 | $4K | |
| 82274 | <1% | 451 | $3K | |
| 86765 | <1% | 348 | $3K | |
| 84436 | <1% | 1,026 | $3K | |
| 80369 | <1% | 1,064 | $3K | |
| 83002 | <1% | 276 | $3K | |
| 87255 | <1% | 200 | $3K | |
| 82105 | <1% | 355 | $3K | |
| 86735 | <1% | 345 | $3K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 15 | $3K |
| 82677 | <1% | 170 | $2K | |
| 83021 | <1% | 216 | $2K | |
| 82950 | <1% | 714 | $2K | |
| 80076 | <1% | 641 | $2K | |
| 86140 | <1% | 1,079 | $2K | |
| 82627 | <1% | 154 | $2K | |
| 86376 | <1% | 235 | $2K | |
| 85652 | <1% | 1,676 | $2K | |
| 83735 | <1% | 553 | $2K | |
| 80368 | <1% | 962 | $2K | |
| 82150 | <1% | 485 | $2K | |
| 82248 | <1% | 598 | $2K | |
| 80339 | <1% | 161 | $2K | |
| 84550 | <1% | 691 | $2K | |
| 86431 | <1% | 599 | $2K | |
| 82652 | <1% | 123 | $1K | |
| 86336 | <1% | 173 | $1K | |
| 85610 | <1% | 926 | $1K | |
| 80055 | <1% | 31 | $1K | |
| 82977 | <1% | 350 | $1K | |
| 87650 | <1% | 88 | $1K | |
| 80164 | <1% | 299 | $1K | |
| 84144 | <1% | 127 | $1K | |
| 86317 | <1% | 167 | $1K | |
| 83690 | <1% | 324 | $1K | |
| 87147 | <1% | 458 | $1K | |
| 84480 | <1% | 237 | $1K | |
| 82784 | <1% | 132 | $1K | |
| 83013 | <1% | 25 | $1K | |
| 84450 | <1% | 302 | $1K | |
| 87209 | <1% | 169 | $1K | |
| 80184 | <1% | 158 | $974.34 | |
| 82947 | <1% | 377 | $909.05 | |
| 84460 | <1% | 301 | $905.35 | |
| 84479 | <1% | 352 | $861.80 | |
| 87329 | <1% | 178 | $814.17 | |
| 82785 | <1% | 131 | $811.23 | |
| 86235 | <1% | 29 | $788.26 | |
| 87480 | <1% | 72 | $766.42 | |
| 87510 | <1% | 72 | $766.42 | |
| 87660 | <1% | 73 | $757.77 | |
| 87338 | <1% | 83 | $727.00 | |
| 86039 | <1% | 131 | $650.58 | |
| 87177 | <1% | 169 | $570.65 | |
| 87102 | <1% | 134 | $569.34 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 15 | $555.84 |
| 86800 | <1% | 53 | $535.86 | |
| 83516 | <1% | 81 | $517.60 | |
| 86200 | <1% | 89 | $510.90 | |
| 85018 | <1% | 374 | $507.33 | |
| 82565 | <1% | 157 | $477.01 | |
| 84156 | <1% | 192 | $438.29 | |
| 82951 | <1% | 75 | $419.04 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 67 | $406.08 |
| 84165 | <1% | 92 | $401.48 | |
| 86850 | <1% | 159 | $397.46 | |
| 86901 | <1% | 180 | $388.23 | |
| 82550 | <1% | 115 | $375.40 | |
| 84155 | <1% | 166 | $356.42 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 1,228 | $352.20 |
| 80178 | <1% | 92 | $351.30 | |
| 84154 | <1% | 30 | $320.97 | |
| 84100 | <1% | 129 | $295.07 | |
| 86334 | <1% | 29 | $287.38 | |
| 85014 | <1% | 193 | $284.01 | |
| 82247 | <1% | 114 | $280.68 | |
| 84703 | <1% | 53 | $269.31 | |
| 82533 | <1% | 28 | $251.55 | |
| 80323 | <1% | 31 | $245.92 | |
| 81003 | <1% | 236 | $235.00 | |
| 80356 | <1% | 54 | $227.66 | |
| 80365 | <1% | 44 | $222.81 | |
| 87205 | <1% | 95 | $221.72 | |
| 84520 | <1% | 73 | $219.85 | |
| 87150 | <1% | 13 | $181.26 | |
| 80358 | <1% | 64 | $175.67 | |
| 86900 | <1% | 91 | $172.92 | |
| 85730 | <1% | 70 | $172.03 | |
| 82040 | <1% | 61 | $169.14 | |
| 84270 | <1% | 13 | $157.72 | |
| 82310 | <1% | 113 | $146.05 | |
| 86705 | <1% | 24 | $139.87 | |
| 87625 | <1% | 12 | $138.67 | |
| 80069 | <1% | 31 | $125.68 | |
| 82465 | <1% | 48 | $97.76 | |
| 86709 | <1% | 17 | $88.74 | |
| 84075 | <1% | 29 | $87.35 | |
| 83525 | <1% | 12 | $86.75 | |
| 83721 | <1% | 33 | $84.40 | |
| 85041 | <1% | 33 | $56.91 | |
| 83615 | <1% | 15 | $38.60 | |
| 85045 | <1% | 16 | $30.12 | |
| 85048 | <1% | 18 | $26.38 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOWLES, CHARLES (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.